We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Acrux Limited is a biotechnology business based in Australia. Acrux shares (ACR) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Acrux has a trailing 12-month revenue of around $1.3 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | $0.115 - $0.22 |
|---|---|
| 50-day moving average | $0.1253 |
| 200-day moving average | $0.1376 |
| Target price | $0.23 |
| PE ratio | N/A |
| Dividend yield | $0.06 (50%) |
| Earnings per share (TTM) | $-0.057 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.12
| 1 week (2021-09-16) | -11.11% |
|---|---|
| 1 month (2021-08-26) | -7.69% |
| 3 months (2021-06-25) | -11.11% |
| 6 months (2021-03-26) | -22.58% |
| 1 year (2020-09-25) | -31.43% |
|---|---|
| 2 years (2019-09-26) | -33.33% |
| 3 years (2018-09-26) | -44.19% |
| 5 years (2016-09-26) | -65.22% |
| Revenue TTM | $1.3 million |
|---|---|
| Gross profit TTM | $-7,591,000 |
| Return on assets TTM | -49.35% |
| Return on equity TTM | -80.64% |
| Profit margin | 0% |
| Book value | 0.065 |
| Market capitalisation | $34 million |
TTM: trailing 12 months
We're not expecting Acrux to pay a dividend over the next 12 months.
Over the last 12 months, Acrux's shares have ranged in value from as little as $0.115 up to $0.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Acrux's is 0.9458. This would suggest that Acrux's shares are less volatile than average (for this exchange).
Acrux Limited, together with its subsidiaries, develops and commercializes generic and specialty topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. Acrux Limited was incorporated in 1998 and is based in West Melbourne, Australia.
Everything we know about the Cosmos Exploration IPO, plus information on how to buy in.
Shares in BNPL provider Zip Co have slipped more than 13% in the last 6 months.
Shares in electricity giant AGL Energy are down 60% in the last 12 months.
Everything we know about the Dundas Minerals IPO, plus information on how to buy in.
Everything we know about the Kalgoorlie Gold Mining IPO, plus information on how to buy in.
We look at some of the biggest and best performing iron ore stocks in Australia.
Shares in the major banks have risen more than 50% in the last 12 months.
Steps to owning and managing China Evergrande Group shares from Australia.
Virgin Australia launches more direct Tassie services with flexible flights taking off from October 2021.
Everything we know about the Hamelin Gold IPO, plus information on how to buy in.
